BBIO
BridgeBio Pharma, Inc.Company Information
- Company Name
- BridgeBio Pharma, Inc.
- CIK
- CIK0001743881
- Category
- Large accelerated filer
- Ticker: Exchange
- BBIO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- BBIO
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-17
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 1,308,968
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 190,134,319
- Shares outstanding
- 195,785,884
- Ownership
- 97.11%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- -11.61%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| One Point Seven Five Percentage Convertible Senior Notes Due Two Thousand And Thirty One | - | - | - | - | 559 | 5 | - | - | - | - | - | - | ||||||
| A2027 Convertible Senior Notes | 0 | 547 | 547 | 547 | 0 | 0 | 545 | 0 | - | - | - | - | ||||||
| Two Point Two Five Percentage Convertible Senior Notes Due Two Thousand And Twenty Nine | - | - | - | - | 1 | 739 | 748 | -0 | 0 | 0 | 737 | 0 | ||||||
| Term Loan | - | - | 0 | 0 | - | - | 437 | - | - | - | - | - | ||||||
| Equity Securities Fv Ni | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 59 | 38 | ||||||
| A2029 Convertible Senior Notes | 1 | 741 | 741 | 740 | 0 | 0 | 739 | 0 | - | - | - | - | ||||||
| A2031 Convertible Senior Notes | 0 | 565 | 565 | 564 | -575 | 575 | 0 | - | - | - | - | - | ||||||
| Two Point Five Zero Percentage Convertible Senior Notes Due Two Thousand And Twenty Seven | - | - | - | - | -4 | 550 | 34 | -0 | 0 | 0 | 543 | 0 | ||||||
| A2033 Convertible Senior Notes | 0 | 620 | - | - | - | 0 | - | - | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 678 | 880 | 570 | 643 | 749 | 541 | 681 | 266 | 408 | 475 | 376 | 505 | ||||||
| Receivables Long Term Contracts Or Programs | - | - | - | - | - | - | - | 0 | 1 | 235 | 2 | 5 | ||||||
| Restricted Cash Current | - | - | 1 | - | - | - | 0 | 139 | 139 | 0 | 17 | 17 | ||||||
| Available For Sale Securities Debt Securities Current | 42 | 60 | 17 | 3 | 8 | - | 0 | - | 40 | 44 | 0 | 0 | ||||||
| Accounts Receivable Net Current | 254 | 205 | 139 | 117 | 77 | 115 | 5 | - | - | - | 2 | - | ||||||
| Inventory Net | 53 | 33 | 27 | 25 | 18 | 4 | 0 | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 66 | 63 | 44 | 52 | 60 | 35 | 35 | 38 | 28 | 28 | 24 | 23 | ||||||
| Assets Current | 1,093 | 1,241 | 798 | 839 | 912 | 695 | 721 | 445 | 616 | 783 | 478 | 588 | ||||||
| Investments In Affiliates Subsidiaries Associates And Joint Ventures | - | - | - | 92 | 108 | 128 | 144 | 160 | 117 | - | 0 | - | ||||||
| Equity Method Investments | 55 | 62 | 80 | - | - | - | 144 | - | - | - | - | - | ||||||
| Property Plant And Equipment Net | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 9 | 10 | 11 | 12 | 12 | ||||||
| Operating Lease Right Of Use Asset | 17 | 17 | 8 | 7 | 6 | 7 | 6 | 6 | 7 | 8 | 8 | 9 | ||||||
| Intangible Assets Net Excluding Goodwill | 27 | 27 | 28 | 29 | 30 | 28 | 24 | 25 | 25 | 26 | 26 | 27 | ||||||
| Other Assets Noncurrent | 20 | 19 | 17 | 26 | 18 | 17 | 18 | 20 | 19 | 21 | 23 | 19 | ||||||
| Assets | 1,217 | 1,371 | 936 | 998 | 1,080 | 882 | 919 | 665 | 794 | 849 | 546 | 655 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 27 | 29 | 36 | 19 | 26 | 28 | 10 | 13 | 18 | 5 | 11 | 4 | ||||||
| Employee Related Liabilities Current | 50 | 39 | 77 | 56 | 37 | 33 | 58 | 44 | 29 | 32 | 57 | 34 | ||||||
| Operating Lease Liability Current | 3 | 4 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | ||||||
| Deferred Revenue Current | - | - | - | - | 11 | 12 | 15 | 12 | 15 | 14 | 6 | 7 | ||||||
| Contract With Customer Liability Current | 6 | 6 | 7 | 9 | - | - | 15 | - | - | - | - | - | ||||||
| Liabilities Current | 891 | 816 | 288 | 217 | 176 | 152 | 154 | 139 | 134 | 141 | 144 | 106 | ||||||
| Long Term Debt Noncurrent | - | - | - | - | 0 | 0 | 437 | 436 | 435 | 435 | 446 | 442 | ||||||
| Operating Lease Liability Noncurrent | 15 | 14 | 4 | 3 | 4 | 5 | 5 | 6 | 7 | 8 | 9 | 10 | ||||||
| Deferred Revenue Noncurrent | - | - | - | - | 15 | 18 | 17 | 19 | 17 | 20 | 4 | - | ||||||
| Contract With Customer Liability Noncurrent | 10 | 12 | 13 | 13 | - | - | 17 | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 6 | 12 | ||||||
| Liabilities | 3,723 | 3,640 | 3,013 | 2,921 | 2,859 | 2,520 | 2,377 | 1,883 | 1,876 | 1,886 | 1,889 | 1,849 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | - | 0 | 0 | - | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Value | - | - | - | - | -323 | -323 | -275 | -275 | -275 | -275 | -275 | -275 | ||||||
| Treasury Stock Common Value | -533 | -406 | -323 | -323 | - | - | -275 | - | - | - | - | - | ||||||
| Additional Paid In Capital | 2,155 | 2,112 | 2,058 | 2,018 | 1,981 | 1,938 | 1,903 | 1,876 | 1,851 | 1,821 | 1,481 | 1,460 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -4,137 | -3,985 | -3,821 | -3,628 | -3,446 | -3,264 | -3,096 | -2,831 | -2,669 | -2,596 | -2,561 | -2,392 | ||||||
| Stockholders Equity | -2,515 | -2,268 | -2,087 | -1,923 | -1,788 | -1,648 | -1,468 | -1,230 | -1,093 | -1,050 | -1,343 | -1,195 | ||||||
| Minority Interest | 10 | 10 | 11 | 10 | 10 | 10 | 10 | 11 | 11 | 12 | 11 | 12 | ||||||
| Liabilities And Stockholders Equity | 1,217 | 1,371 | 936 | 998 | 1,080 | 882 | 919 | 665 | 794 | 849 | 546 | 655 | ||||||
| Related Party | 2 | 4 | 2 | 2 | - | - | - | - | - | - | - | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 206 | 204 | 202 | 200 | 199 | 197 | 196 | 195 | 194 | 193 | 181 | 180 | ||||||
| Shares Outstanding | 195 | 196 | 195 | 193 | 191 | 190 | 190 | 189 | 188 | 187 | 175 | 174 | ||||||
| Treasury Stock Common Shares | 11 | 9 | 8 | 8 | 8 | 8 | 6 | 6 | 6 | 6 | 6 | 6 | ||||||
| Other Liabilities Current | 192 | 136 | 120 | 93 | 66 | 41 | 33 | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBridgeBio Pharma, Inc. (BBIO) — SEC Financial Statements & Analysis
BridgeBio Pharma, Inc. (BBIO) is a pharmaceutical preparations company, incorporated in DE. BridgeBio Pharma, Inc. trades on Nasdaq as: BBIO. BridgeBio Pharma, Inc. (BBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, BridgeBio Pharma, Inc. carries a market cap of $14.58B, a P/E ratio of -20.78x, a P/B ratio of -5.80x, a P/S ratio of 20.45x, an enterprise value of $13.90B, and an EV/EBITDA multiple of -28.22x. On profitability, it posts a gross margin of 94.44%, an operating margin of -69.81%, a net margin of -98.40%, a Return on Equity (ROE) of 32.61%, and a Return on Assets (ROA) of -61.08%. Per share, it reports EPS of $-3.58, diluted EPS of $-3.58, free cash flow per share of $-2.22, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 202.39% year-over-year, net income growth of -9.49% year-over-year, and EPS growth of -11.92% year-over-year. On the balance sheet, it maintains a current ratio of 1.23x, a quick ratio of 1.09x, working capital of $202.49M, a debt-to-equity ratio of -1.48x, a debt ratio of 3.06, an interest coverage ratio of -10.04x, free cash flow of $-435.39M (TTM), and net debt of $-677.91M. Figures sourced from SEC EDGAR.
- Market Cap
- $14.58B
- P/E TTM
- -20.78x
- EPS TTM
- $-3.58
- P/B TTM
- -5.80x
- ROE TTM
- 32.61%
- ROA TTM
- -61.08%
- Debt To Equity
- -1.48x
- Free Cash Flow TTM
- $-435.39M
- Net Revenue TTM Growth 1Y
- 202.39%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is BridgeBio Pharma, Inc. in?
BridgeBio Pharma, Inc. (BBIO) operates in the Pharmaceutical Preparations industry.
What exchange does BBIO trade on?
BridgeBio Pharma, Inc. (BBIO) trades on the Nasdaq.
Where is BridgeBio Pharma, Inc. incorporated?
BridgeBio Pharma, Inc. is incorporated in DE.
When was BridgeBio Pharma, Inc. (BBIO)'s most recent SEC filing?
BridgeBio Pharma, Inc. (BBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is BBIO's market cap?
BridgeBio Pharma, Inc. (BBIO) has a market capitalization of $14.58B as of 2026-06-30.
What is BBIO's EPS (earnings per share)?
BridgeBio Pharma, Inc. (BBIO)'s trailing twelve month EPS is $-3.58 as of 2026-06-30.
What is BBIO's ROE (return on equity)?
BridgeBio Pharma, Inc. (BBIO)'s trailing twelve month Return on Equity (ROE) is 32.61% as of 2026-06-30.
What is BBIO's ROA (return on assets)?
BridgeBio Pharma, Inc. (BBIO)'s trailing twelve month Return on Assets (ROA) is -61.08% as of 2026-06-30.
What is BBIO's EV/EBITDA?
BridgeBio Pharma, Inc. (BBIO)'s trailing twelve month EV/EBITDA is -28.22x as of 2026-06-30.